Herold Advisors Inc. Acquires 1,533 Shares of GSK plc (NYSE:GSK)

Herold Advisors Inc. lifted its holdings in shares of GSK plc (NYSE:GSKGet Rating) by 4.7% during the 2nd quarter, Holdings Channel reports. The firm owned 34,485 shares of the pharmaceutical company’s stock after purchasing an additional 1,533 shares during the period. Herold Advisors Inc.’s holdings in GSK were worth $1,501,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Gotham Asset Management LLC bought a new position in GSK in the fourth quarter valued at approximately $200,000. Glassman Wealth Services increased its stake in GSK by 71.3% in the fourth quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after acquiring an additional 261 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in GSK by 11.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 235,377 shares of the pharmaceutical company’s stock valued at $10,379,000 after acquiring an additional 24,069 shares during the last quarter. Mutual Advisors LLC increased its stake in GSK by 54.5% in the fourth quarter. Mutual Advisors LLC now owns 20,653 shares of the pharmaceutical company’s stock valued at $911,000 after acquiring an additional 7,282 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in GSK in the fourth quarter valued at approximately $380,000. 16.86% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of a number of research reports. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. UBS Group decreased their target price on shares of GSK from GBX 1,876 ($22.67) to GBX 1,850 ($22.35) in a research note on Wednesday, July 20th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a research note on Wednesday, September 7th. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Thursday, September 8th. Finally, AlphaValue cut shares of GSK to a “reduce” rating in a research note on Tuesday, July 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $1,700.00.

GSK Trading Down 2.2 %

Shares of NYSE:GSK traded down $0.65 during mid-day trading on Friday, reaching $29.36. 9,066,187 shares of the company’s stock were exchanged, compared to its average volume of 5,784,756. The firm has a market capitalization of $59.71 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 1.13 and a beta of 0.61. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.31 and a current ratio of 1.43. GSK plc has a twelve month low of $29.09 and a twelve month high of $46.97. The business’s fifty day moving average price is $35.90 and its 200-day moving average price is $40.93.

GSK (NYSE:GSKGet Rating) last released its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.11. The business had revenue of $8.71 billion for the quarter, compared to analyst estimates of $9.35 billion. GSK had a net margin of 12.91% and a return on equity of 27.84%. On average, research analysts predict that GSK plc will post 3.23 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be issued a $0.383 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Thursday, August 18th. This represents a $1.53 annualized dividend and a yield of 5.22%. GSK’s payout ratio is presently 50.66%.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.